Understand the source comparison
Comparison table
Factor Semaglutide (Ozempic) BRP Peptide Mechanism GLP-1 receptor agonist Unknown receptor, CREB-FOS pathway Target location Brain, gut, pancreas Hypothalamus specifically GI side effects Common (40%+ of patients) Not observed in animals Muscle loss Up to 20%
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Factor
- Semaglutide (Ozempic)
- BRP Peptide
- Mechanism
- GLP-1 receptor agonist
- Unknown receptor, CREB-FOS pathway
- Target location
- Brain, gut, pancreas
- Hypothalamus specifically
- GI side effects
- Common (40%+ of patients)
- Not observed in animals
- Muscle loss
- Up to 20% of weight lost
- Not observed, fat-specific
- Effect on blood sugar
- Lowers glucose directly
- Improves glucose via weight loss
- Human trial data
- Extensive (FDA approved)
- None yet (preclinical)
- Administration
- Weekly injection
- Unknown (daily in studies)
- Availability
- Prescription (approved drug)
- Research use only